Cite
MLA Citation
Z. Xu et al.. “P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA.” HemaSphere, vol. 6, n.d., pp. 937–938. http://access.bl.uk/ark:/81055/vdc_100159756159.0x000004